Variantyx secured $41.5M in series C funding round

The proprietary whole genome sequencing and analysis platforms created by Variantyx improve the understanding of individual patients’ personal genetic composition and assist Healthcare professionals in providing an accurate diagnosis in addition to highly personalized treatments. 

The company’s solutions are currently meant for use in several medical fields, including rare genetic disorders, reproductive health, and precision oncology. Variantyx’s cutting-edge precision oncology solution is meant to analyze and map the unique genetic alterations in a patient’s cancerous tumor to help predict the response to various therapies and recommend the most effective course of medical treatment.

You can read more here.